EJ
Elavanthra Janardhanan Jyothis
About Elavanthra Janardhanan Jyothis
Data last updated:
Elavanthra Janardhanan Jyothis has 6 years in corporate governance. Holds Director role. Currently with 1 company, including Mekiro Pharmaceutical Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Mekiro Pharmaceutical Private Limited at ₹1.62 Cr (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 15 Jan 2020 | 2020 | ₹1.62 Cr (FY 2024) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Elavanthra Janardhanan Jyothis
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Elavanthra Janardhanan Jyothis
Elavanthra Janardhanan Jyothis has 6 years in corporate governance. Holds Director role. Currently with 1 company, including Mekiro Pharmaceutical Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Mekiro Pharmaceutical Private Limited at ₹1.62 Cr (FY 2024).
Elavanthra Janardhanan Jyothis is associated with 1 company as Director, including Mekiro Pharmaceutical Private Limited (₹1.62 Cr).
Elavanthra Janardhanan Jyothis has expertise in General Business.
Elavanthra Janardhanan Jyothis has 6 years in corporate governance.
By reported revenue, the largest current company of Elavanthra Janardhanan Jyothis is Mekiro Pharmaceutical Private Limited, with revenue of ₹1.62 Cr (FY 2024).
Elavanthra Janardhanan Jyothis currently holds positions at 1 company: Mekiro Pharmaceutical Private Limited (₹1.62 Cr).